All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Pharmacy Transplant Series: Managing Infectious Complications with a Focus on CMV

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

Don't miss Part 1! CLICK HERE for Part 1 of this CE activity ►


This is a product jointly developed by the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)


Pharmacists are often a key part of a successful organ transplant team and incredibly important in improving patient adherence with medications and optimizing overall patient outcomes. Transplant patients are often discharged with 10 or more medications. Many of these patients are faced with complex and changing medication regimens, financial strain and possibly even the lack of a support system. Health-system and specialty pharmacies are in a unique position to improve the transplant patient’s adherence to their medication. Additionally, pharmacists serve as a key resource to other health providers on the transplant team.

The Pharmacy Transplant Series is designed to help pharmacists better understand the very complicated post-transplant immunosuppressive regimens, the basics of immunosuppression and the issues related to infections during the post-transplant period. A particular focus on CMV prophylaxis and treatment regimens will be included.

Learning Objectives

At the completion of this webinar, the participant will be able to:

  • Identify infections that patients are at risk for in the post-transplant period.
  • Recommend appropriate CMV prophylaxis and treatment regimens, utilizing primary literature.
  • Outline strategies to assist transplant patients with medication adherence.


Monica V. (Golik) Mahoney, PharmD, BCPS-AQ ID
Clinical Pharmacy Coordinator - Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Planning Committee

Carly D'Agostino, PharmD, BCPS
Clinical Pharmacist, Solid Organ Transplant - Team Lead
Northwestern Memorial Hospital

Donna B. Filo, RPh
Pharmacy Manager
Amber Pharmacy

Nishita Hira, PharmD, CSP
Clinical Program Manager, Specialty Pharmacy
Cystic Fibrosis/Transplant
AllianceRx Walgreens Prime

Monica V. Mahoney, PharmD, BCPS-AQ ID
Clinical Pharmacy Coordinator - Infectious Diseases
Beth Israel Deaconess Medical Center


Release Date: February 27, 2018
Expiration Date: February 27, 2021


ACPE LogoThis activity is jointly provided by ProCE, Inc., the National Association of Specialty Pharmacy (NASP) and the Society of Infectious Diseases Pharmacists (SIDP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-082-H01-P has been assigned to this home-study knowledge-based activity (initial release date February 27, 2018). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. D’Agostino, Donna Filo and Nishita Hira do not have any relevant commercial and/or financial relationships to disclose. Dr. Mahoney is an Advisory Board member for Cutis Pharma, Melinta Therapeutics, and Roche Pharmaceuticals/Diagnostics; is a Consultant for Group Dynamics in Focus, Krog & Partners, Inc., and Navigant Consulting; and involved in research funded by Forest Pharmaceuticals.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is supported by educational grants from Bristol-Myers Squibb and Shire.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.